The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan

Ting Chi Yeh, Hsi Che Liu, Lin Yen Wang, Shu Huey Chen, Wei Ying Lin, Der Cherng Liang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79%, 92%, and 98% after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64%±6.9% (SE), and the 5-year event-free survival was 60%±7.1%; for non-APL AML, the rates were 62%±7.5% and 59%±7.6%; for APL, 83±15.2 and 67±19.3%. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Acute promyelocytic leukemia
  • Outcome
  • Protocol design
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan'. Together they form a unique fingerprint.

  • Cite this